Скачать с ютуб JAVELIN Bladder 100: Avelumab maintenance for metastatic or locally advanced bladder cancer в хорошем качестве
JAVELIN Bladder 100: Avelumab maintenance for metastatic or locally advanced bladder cancer
2 года назад
Speaker: Joaquim Bellmunt
Institution: Harvard Medical School
Institution: Dana-Farber Cancer Institute
Event: ASCO 2022
Format: Interview
Subject: Bladder Cancer
Subject: Urothelial Carcinoma
Subject: Genitourinary Cancer
Field: Treatment
Field: Trial Updates
Field: Immuno-Oncology
Medicines: Avelumab
Trial: JAVELIN Bladder 100
NCT02603432
Medicines: Antibodies
Скачать бесплатно и смотреть ютуб-видео без блокировок JAVELIN Bladder 100: Avelumab maintenance for metastatic or locally advanced bladder cancer в качестве 4к (2к / 1080p)
У нас вы можете посмотреть бесплатно JAVELIN Bladder 100: Avelumab maintenance for metastatic or locally advanced bladder cancer или скачать в максимальном доступном качестве, которое было загружено на ютуб. Для скачивания выберите вариант из формы ниже:
Загрузить музыку / рингтон JAVELIN Bladder 100: Avelumab maintenance for metastatic or locally advanced bladder cancer в формате MP3:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса savevideohd.ru
JAVELIN Bladder 100: Avelumab maintenance for metastatic or locally advanced bladder cancer
Joaquim Bellmunt, MD, PhD, Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA, discusses the JAVELIN Bladder 100 study (NCT02603432), which investigated avelumab maintenance therapy for patients with metastatic or locally advanced bladder cancer. Patients who did not progress after receiving 4-6 cycles of first-line cisplatin-based chemotherapy were randomised to receive either avelumab maintenance plus best supportive care vs best supportive care alone, with a primary endpoint of overall survival. Results published in 2020 showed a significant survival benefit for avelumab maintenance therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Comments
